| Number of patients |
8 |
8 |
17 |
| Hours from bite to hospitalization: median (range) |
3.0 (1.5–6.0) |
3.0 (1.0–6.0) |
3.3 (1.5–7.0) |
| Days of hospital stay: median (range) |
2 (1–3) |
3 (2–3) |
8 (4–12) |
| Neurotoxicity |
| Maximum ptosis observed |
|
|
|
| • Partial |
- |
7 (87.5%) |
5 (29.4%) |
| • Complete |
- |
1 (12.5%) |
12 (70.6%) |
| Maximum ophthalmoplegia observed |
|
|
|
| • Partial |
- |
1 (12.5%) |
3 (17.6%) |
| • Complete |
- |
0 |
14 (82.4%) |
| Strabismus |
- |
- |
11 (64.7%) |
| Facial weakness |
- |
1 (12.5%) |
17 (100%) |
| Neck flexion weakness (power <5) |
- |
- |
15 (88.2%) |
| Difficulty in swallowing |
- |
- |
17 (100%) |
| Low pitched voice |
- |
- |
12 (70.6%) |
| Tidal volume <250ml |
- |
- |
17 (100%) |
| Reduced upper limb power (Power <5) |
- |
- |
12 (70.6%) |
| Reduced lower limb power (power <5) |
- |
- |
5 (29.4%) |
| Diminished or absent deep tendon reflexes |
|
|
9 (52.9%) |
| Intubation and mechanical ventilation |
- |
- |
17 (100%) |
| Autonomic features |
- |
- |
6 (35.3%) |
| Other features of envenoming |
| Generalized myalgia |
3 (32.7%) |
2 (25%) |
7 (41.2%) |
| Generalized muscle tenderness |
2 (25%) |
2 (25%) |
7 (41.2%) |
| Local envenoming |
5 (62.5%) |
6 (75%) |
9 (52.9%) |
| Non-specific systemic envenoming |
- |
5 (62.5%) |
13 (76.5%) |
| Treatment |
| Antivenom given |
- |
6 (75%) |
17 (100%) |
| Hours from bite to antivenom: median(range) |
- |
7.5 (2.8–13.0) |
3.5 (2.8–7.2) |
| Adverse reactions to antivenom |
- |
6 (100%) |
13 (76.5%) |
